Lassa antiviral LHF-535 protects guinea pigs from lethal challenge

LHF-535 is a small molecule antiviral currently in development for the treatment of Lassa fever, a zoonotic disease endemic in West Africa that generates significant morbidity and mortality. Current treatment options are inadequate, and there are no approved therapeutics or vaccines for Lassa fever....

Descripción completa

Detalles Bibliográficos
Autores principales: Cashman, Kathleen A., Wilkinson, Eric R., Posakony, Jeffrey, Madu, Ikenna G., Tarcha, Eric J., Lustig, Kurt H., Korth, Marcus J., Bedard, Kristin M., Amberg, Sean M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675838/
https://www.ncbi.nlm.nih.gov/pubmed/36402782
http://dx.doi.org/10.1038/s41598-022-23760-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675838/
https://www.ncbi.nlm.nih.gov/pubmed/36402782
http://dx.doi.org/10.1038/s41598-022-23760-2

Ejemplares similares